GlassScriptPhysician profile
Michelle Anderson
NPI 1013302496
$2,581.68
in general payments reported to CMS, 2019-2025
22 companies · $923 in 2025
The $923 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $636 · 2023: $519 · 2024: $258 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $808.48 | 2021-2024 | Farxiga, Andexxa |
| Ardelyx, INC. | $251.38 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Novartis Pharmaceuticals Corporation | $242.90 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $157.72 | 2022-2023 | Korsuva, Velphoro |
| Medtronic, INC. | $126.48 | 2023 | Endurant Iis |
| Biohaven Pharmaceutical Holding Company LTD. | $124.68 | 2022 | |
| Calliditas Therapeutics US INC. | $117.62 | 2024-2025 | Tarpeyo |
| Akebia Therapeutics INC | $104.76 | 2025 | Vafseo |
| Laborie Medical Technologies Corp. | $93.12 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Travere Therapeutics, INC. | $73.66 | 2025 | Filspari |
| Urovant Sciences INC | $69.30 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.51 | 2025 | |
| Amgen INC. | $61.68 | 2023 | Parsabiv, Tavneos |
| Coloplast Corp | $54.70 | 2025 | |
| Leadiant Biosciences, INC. | $37.73 | 2023 | Carnitor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.65 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $35.09 | 2023-2025 | Livtencity |
| Genzyme Corporation | $32.46 | 2023 | |
| Kyowa Kirin, INC. | $27.15 | 2024 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $21.31 | 2024 | Jynarque |
| Cormedix INC. | $19.22 | 2025 | Defencath |
| Boston Scientific Corporation | $19.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.